| scholarly article | Q13442814 |
| P2093 | author name string | Karen A Robinson | |
| Bruce C Marshall | |||
| Kathryn A Sabadosa | |||
| Antoinette Moran | |||
| Arlene Stecenko | |||
| Bonnie Slovis | |||
| Carol Brunzell | |||
| CFRD Guidelines Committee | |||
| Gary Onady | |||
| Marcia Katz | |||
| Richard C Cohen | |||
| P2860 | cites work | Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality | Q22255438 |
| Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis | Q30662248 | ||
| Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study | Q33247492 | ||
| Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications | Q33264765 | ||
| A multicenter, randomized trial of treatment for mild gestational diabetes | Q33583959 | ||
| Diagnosis of cystic fibrosis related diabetes: a selective approach in performing the oral glucose tolerance test based on a combination of clinical and biochemical criteria | Q33644742 | ||
| Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report | Q33739945 | ||
| Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management | Q34331668 | ||
| Hyperglycemia and adverse pregnancy outcomes | Q34777029 | ||
| Consensus report on nutrition for pediatric patients with cystic fibrosis | Q34917340 | ||
| Glargine versus NPH insulin in cystic fibrosis related diabetes | Q36710309 | ||
| Microvascular complications in cystic fibrosis-related diabetes. | Q36745248 | ||
| Glucose tolerance in patients with cystic fibrosis: five year prospective study | Q36905808 | ||
| Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review | Q37149541 | ||
| Sex disparities in effects of cystic fibrosis-related diabetes on clinical outcomes: a matched study. | Q37185504 | ||
| Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1 | Q37319146 | ||
| Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial | Q37364992 | ||
| Oral glucose tolerance testing in children with cystic fibrosis | Q37377703 | ||
| Cystic fibrosis pulmonary guidelines: airway clearance therapies | Q37425285 | ||
| Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline | Q40747884 | ||
| Management dilemmas in the individual with cystic fibrosis and diabetes | Q40795852 | ||
| Diabetic microangiopathy in patients with cystic fibrosis | Q41767672 | ||
| Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy | Q43724010 | ||
| Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes | Q43748972 | ||
| How do adults with cystic fibrosis cope following a diagnosis of diabetes? | Q43749886 | ||
| Nutritional decline in cystic fibrosis related diabetes: the effect of intensive nutritional intervention | Q43864483 | ||
| Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis | Q44259350 | ||
| Glucose intolerance in children with cystic fibrosis | Q44313484 | ||
| Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis | Q44453246 | ||
| Impact of pregnancy on women with cystic fibrosis | Q44487468 | ||
| Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia | Q44490291 | ||
| Living with cystic fibrosis-related diabetes or type 1 diabetes mellitus: a comparative study exploring health-related quality of life and patients' reported experiences of hypoglycaemia. | Q44559197 | ||
| Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit | Q45068572 | ||
| Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis. | Q45298887 | ||
| Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an 'orphan' area? A retrospective case-control study | Q46120519 | ||
| One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. | Q46126609 | ||
| Use of the insulin pump in treat cystic fibrosis related diabetes | Q46151372 | ||
| No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes | Q46315068 | ||
| New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis | Q46414713 | ||
| Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). | Q46488650 | ||
| Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes | Q46570689 | ||
| The metabolic effects of pregnancy in cystic fibrosis | Q46628054 | ||
| Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. | Q46637181 | ||
| Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance | Q46642107 | ||
| Continuous glucose monitoring in adolescents with cystic fibrosis | Q46719455 | ||
| Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes | Q46884875 | ||
| Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis | Q47739161 | ||
| A teenage girl with cystic fibrosis-related diabetes, diabetic ketoacidosis, and cerebral edema | Q48935663 | ||
| Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. | Q50558069 | ||
| Evaluation of glucose tolerance and insulin secretion in cystic fibrosis patients. | Q50905243 | ||
| Long-term effect of insulin treatment in cystic fibrosis-related diabetes. | Q51108957 | ||
| Spontaneous hypoglycemia in patients with cystic fibrosis. | Q51476993 | ||
| Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. | Q51522306 | ||
| Pancreatic endocrine function in cystic fibrosis. | Q51610960 | ||
| Intermediate-term results of heart-lung transplantation for cystic fibrosis | Q67517651 | ||
| Diabetes mellitus associated with cystic fibrosis | Q68276767 | ||
| Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections | Q72860267 | ||
| HbA1c is not recommended as a screening test for diabetes in cystic fibrosis | Q73905088 | ||
| Predictors of deterioration of lung function in cystic fibrosis | Q74054944 | ||
| Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome | Q74493859 | ||
| Diabetic retinopathy in adult patients with cystic fibrosis-related diabetes | Q77671027 | ||
| Potential impact of HbA1c determination on clinical decision making in patients with cystic fibrosis-related diabetes | Q77892237 | ||
| The effect of pregnancy on survival in women with cystic fibrosis | Q79157671 | ||
| Combined en bloc liver pancreas transplantation for children with CF | Q79822779 | ||
| Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes? | Q81118889 | ||
| Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation | Q81543145 | ||
| Epidemiology of cystic fibrosis-related diabetes | Q81713930 | ||
| Cystic fibrosis-related diabetes in adults | Q83341770 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | 2697-2708 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society | |
| P478 | volume | 33 |
| Q28067394 | A Practical Approach to Glucose Abnormalities in Cystic Fibrosis |
| Q30410677 | A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis |
| Q39570604 | Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis. |
| Q36499679 | Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets |
| Q39096768 | Adherence to therapies in cystic fibrosis: a targeted literature review. |
| Q38231006 | Advances in the diagnosis and treatment of cystic fibrosis. |
| Q58784432 | An Increase in Chromogranin A-Positive, Hormone-Negative Endocrine Cells in Pancreas in Cystic Fibrosis |
| Q40525694 | Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis |
| Q26861211 | Australian standards of care for cystic fibrosis-related diabetes |
| Q36101665 | Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis |
| Q43538692 | Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. |
| Q38656600 | CF-related diabetes: Containing the metabolic miscreant of cystic fibrosis |
| Q38035939 | Characteristics of diabetes after pediatric liver transplant |
| Q85398004 | Chronic Pancreatitis and Diabetes Mellitus |
| Q42343499 | Clinical care guidelines: too much of a good thing? |
| Q36720341 | Comparison of cystic fibrosis-related diabetes with type 1 diabetes based on a German/Austrian Pediatric Diabetes Registry |
| Q88180158 | Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline |
| Q58737001 | Cystic Fibrosis Mortality in Childhood. Data from European Cystic Fibrosis Society Patient Registry |
| Q39017146 | Cystic Fibrosis and the Nervous System. |
| Q91263415 | Cystic Fibrosis-Related Diabetes Screening in Adults: A Gap Analysis and Evaluation of Accuracy of Glycated Hemoglobin Levels |
| Q55376866 | Cystic Fibrosis-Related Diabetes. |
| Q53090680 | Cystic Fibrosis. |
| Q57820573 | Cystic Fibrosis: Clinical Phenotypes in Children and Adolescents |
| Q89219005 | Cystic fibrosis |
| Q88052350 | Cystic fibrosis related diabetes |
| Q37882620 | Cystic fibrosis related diabetes (CFRD)--the end stage of progressive insulin deficiency |
| Q28655881 | Cystic fibrosis related liver disease--another black box in hepatology |
| Q36605683 | Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions. |
| Q44392974 | Cystic fibrosis-related diabetes in older adolescents: parental support and self-management |
| Q52579658 | Cystic fibrosis-related diabetes is caused by islet loss and inflammation. |
| Q64084453 | Cystic fibrosis-related diabetes: optimizing care with a multidisciplinary approach |
| Q38054190 | Cystic fibrosis: a clinician's tool for management of care advancing into the adult population |
| Q38252636 | Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations |
| Q49335072 | Cystic-fibrosis-related diabetes: time for oral drugs? |
| Q39660074 | Diabetes and primary infertility in young males: do not forget cystic fibrosis |
| Q45762433 | Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases |
| Q28661248 | Diabetes in cystic fibrosis: multicenter screening results based on current guidelines |
| Q35140718 | Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex |
| Q83684170 | Diabetes: cystic fibrosis-related diabetes: where to from here? |
| Q38857042 | Diagnosing cystic fibrosis-related diabetes: current methods and challenges. |
| Q35077819 | Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis |
| Q44881953 | Diagnosis of cystic fibrosis-related glucose abnormalities: Can we shorten the standard oral glucose tolerance test? |
| Q33823923 | Diagnostic contribution of molecular analysis of the cystic fibrosis transmembrane conductance regulator gene in patients suspected of having mild or atypical cystic fibrosis. |
| Q48501787 | Effects of a partially supervised conditioning programme in cystic fibrosis: an international multi-centre randomised controlled trial (ACTIVATE-CF): study protocol |
| Q41659595 | Elevation of one hour plasma glucose during oral glucose tolerance testing. |
| Q38911660 | Endocrine Disorders in Cystic Fibrosis |
| Q52739000 | Evolving Mechanistic Views and Emerging Therapeutic Strategies for Cystic Fibrosis-Related Diabetes. |
| Q38025731 | Exercise as part of a cystic fibrosis therapeutic routine |
| Q37120916 | Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes |
| Q35641585 | Gender differences in outcomes of patients with cystic fibrosis |
| Q37483419 | Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes |
| Q42412088 | Glucose derangements in very young children with cystic fibrosis and pancreatic insufficiency |
| Q34427525 | Glucose tolerance during pulmonary exacerbations in children with cystic fibrosis. |
| Q64082582 | Glucose tolerance in Canadian and French cystic fibrosis adult patients |
| Q38746353 | Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes |
| Q91989883 | Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis |
| Q34506279 | High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study |
| Q24187116 | Home versus hospital intravenous antibiotic therapy for cystic fibrosis |
| Q24201353 | Home versus hospital intravenous antibiotic therapy for cystic fibrosis |
| Q37576093 | Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes |
| Q48301569 | Hyperglycemia in Young Children with Cystic Fibrosis. |
| Q43087675 | Hypoglycemia in adults with cystic fibrosis during oral glucose tolerance testing. |
| Q47938935 | Hypoglycemia is common in children with cystic fibrosis and seen predominantly in females. |
| Q88990308 | Identifying Prediabetes and Type 2 Diabetes in Asymptomatic Youth: Should HbA1c Be Used as a Diagnostic Approach? |
| Q50751448 | Importance of screening with oral glucose tolerance test for early diagnosis of cystic fibrosis-related diabetes mellitus. |
| Q51122607 | Improved screening for cystic fibrosis-related diabetes by an integrated care team using an algorithm. |
| Q36860528 | Improving performance in the detection and management of cystic fibrosis-related diabetes in the Mountain West Cystic Fibrosis Consortium |
| Q48667707 | Improving screening for diabetes in cystic fibrosis. |
| Q90457825 | Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis |
| Q24185897 | Insulin and oral agents for managing cystic fibrosis-related diabetes |
| Q24201034 | Insulin and oral agents for managing cystic fibrosis-related diabetes |
| Q36031080 | Insulin secretion abnormalities in exocrine pancreatic sufficient cystic fibrosis patients |
| Q38781600 | Insulin therapy in patients with cystic fibrosis in the pre-diabetes stage: a systematic review |
| Q85708685 | Ion mobility and liquid chromatography/mass spectrometry strategies for exhaled breath condensate glucose quantitation in cystic fibrosis studies |
| Q36165392 | Iron homeostasis during cystic fibrosis pulmonary exacerbation |
| Q26744593 | Is Gastroparesis Found More Frequently in Patients with Cystic Fibrosis? A Systematic Review |
| Q50044142 | Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure |
| Q26749173 | Islet-intrinsic effects of CFTR mutation |
| Q48239595 | Latest in cystic fibrosis. |
| Q22305306 | Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry |
| Q35942597 | Low glycaemic index dietary interventions in youth with cystic fibrosis: a systematic review and discussion of the clinical implications |
| Q92841151 | Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients |
| Q36658777 | Lung transplantation for cystic fibrosis: results, indications, complications, and controversies |
| Q26858964 | Maintenance of nutritional status in patients with cystic fibrosis: new and emerging therapies |
| Q38178773 | Management of comorbidities in older patients with cystic fibrosis. |
| Q28069386 | Management of pancreatogenic diabetes: challenges and solutions |
| Q89127326 | Methods for Measuring Risk for Type 2 Diabetes in Youth: the Oral Glucose Tolerance Test (OGTT) |
| Q38135327 | Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors |
| Q41700158 | Nationwide trends of hospitalizations for cystic fibrosis in the United States from 2003 to 2013. |
| Q38195431 | New insights into cystic fibrosis-related diabetes in children |
| Q37938722 | Newborn screening and renal disease: where we have been; where we are now; where we are going |
| Q38538310 | Nutrition Management of Cystic Fibrosis in the 21st Century |
| Q55515276 | Nutritional Requirements of Lung Transplant Recipients: Challenges and Considerations. |
| Q35118399 | Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus |
| Q26782591 | Outpatient Management of Pediatric Type 1 Diabetes |
| Q48111387 | Overweight and obesity in patients with cystic fibrosis: a center-based analysis |
| Q47118798 | Patient and parent perceptions of the diagnosis and management of cystic fibrosis-related diabetes. |
| Q47266208 | Pharmacological management of cystic fibrosis related diabetes |
| Q54597124 | Physical Activity Levels in Individuals with Cystic Fibrosis-Related Diabetes. |
| Q36824415 | Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline |
| Q37706330 | Practical guidelines: lung transplantation in patients with cystic fibrosis |
| Q37070420 | Pregnancy and cystic fibrosis: Approach to contemporary management. |
| Q35876643 | Pretransplant HRCT Characteristics Are Associated with Worse Outcome of Lung Transplantation for Cystic Fibrosis Patients |
| Q51207958 | Prevalence of malnutrition and obesity among cystic fibrosis patients. |
| Q42703585 | Prognostic relevance of hypoglycemia following an oral glucose challenge for cystic fibrosis-related diabetes |
| Q47158498 | Reduced β-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance |
| Q47635345 | Relationship between exercise capacity and glucose tolerance in cystic fibrosis. |
| Q47692517 | Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. |
| Q35682983 | Risk factors for chronic kidney disease in adults with cystic fibrosis. |
| Q49334378 | Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease |
| Q38416187 | Screening of glucose metabolism derangements in pediatric cystic fibrosis patients: how, when, why. |
| Q92331303 | Size-adjusted muscle power and muscle metabolism in patients with cystic fibrosis are equal to healthy controls - a case control study |
| Q54265700 | Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial |
| Q35214383 | Sputum glucose and glycemic control in cystic fibrosis-related diabetes: a cross-sectional study |
| Q34425055 | Standards of medical care in diabetes--2011. |
| Q24632533 | Standards of medical care in diabetes--2012 |
| Q29620309 | Standards of medical care in diabetes--2013 |
| Q40749365 | Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes. |
| Q89154748 | Sugar Substitute? |
| Q64099124 | Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis–Related Diabetes |
| Q48123950 | Targeting postprandial glycaemia in children with diabetes: Opportunities and challenges |
| Q38980646 | The 1-h oral glucose tolerance test glucose and insulin values are associated with markers of clinical deterioration in cystic fibrosis |
| Q37417551 | The ICET-A Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients. |
| Q38217187 | The development of diabetes among Danish cystic fibrosis patients over the last two decades. |
| Q36926385 | The ΔF508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Is Associated With Progressive Insulin Resistance and Decreased Functional β-Cell Mass in Mice. |
| Q33702502 | Under Utilization of Pancreas Transplants in Cystic Fibrosis Recipients in the United Network Organ Sharing (UNOS) Data 1987-2014. |
| Q37892766 | Update in cystic fibrosis 2010. |
| Q26830633 | Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD) |
| Q91322272 | Validation of a Stepwise Approach Using Glycated Hemoglobin Levels to Reduce the Number of Required Oral Glucose Tolerance Tests to Screen for Cystic Fibrosis-Related Diabetes in Adults |
| Q46769816 | Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes? |
| Q54283102 | [Other specific types of diabetes]. |
| Q64905864 | β-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose ≥155 mg/dL. |
Search more.